Diabetes & Endocrinology
SGLT2 Inhibitors Linked to Lower Lung Cancer Risk in Patients With COPD and Type 2 Diabetes
A nationwide cohort study found that SGLT2 inhibitor initiation was associated with a 27% lower risk of incident lung cancer in patients with COPD and type 2 diabetes compared with sulfonylureas.

